Workshops

Workshop Title: “Reveal the power of the 6-base genome: how multiomic 6-base data from cell-free DNA enhances the performance of liquid biopsy classifiers and early cancer detection”

Overview: Liquid biopsy (LBX) for profiling cell-free DNA (cfDNA) in blood is a promising method to enhance cancer management through early detection, monitoring and identification of residual disease. Early research focused on detecting actionable somatic mutations, but recent advancements have incorporated methylation. 5-methylcytosine (5mC) profiles of cancer are differential to non-cancer, and recent research has suggested that 5-hydroxymethylcytosine (5hmC) profiles in cfDNA can be a marker for early cancer.

We present a technology that sequences whole genome 6-base data (A, C, G, T, 5mC, and 5hmC) at single base resolution from cfDNA extracted from healthy volunteers and patients with colorectal cancer at stages I-IV. Our findings indicate that separate measurements of 5mC and 5hmC significantly enhance diagnostic accuracy for the detection of stage I CRC (AUC = 0.95) compared to traditional approaches that conflate these markers (modified C, AUC = 0.66). Notably, most regions with an increase in 5hmC in stage I CRC cfDNA also decreased in 5mC in stage IV CRC, suggesting that 5hmC can effectively track regions undergoing demethylation during tumour development. These results support the hypothesis that distinguishing between 5mC and 5hmC can improve the sensitivity of liquid biopsy tests for early cancer detection.  

Speaker: Donna McDade Walker, Vice President, Global Marketing and Product Management

Friday 14th February

7:00am - 8:00am (Breakfast)

Breakfast will be served

Proudly brought to you by:

Workshop Title: “In Vivo mRNA CARs. Advancing the Frontier of In Vivo mRNA CAR Therapy”

Overview:

  1. Setting the stage for the discussion on the progress and future potential of in vivo mRNA CAR therapies.

  2. A comprehensive review of the latest clinical data on mRNA CAR therapies, including safety, efficacy, and patient outcomes.. Key Focus: Highlights of initial clinical findings and their implications for the future of in vivo applications.

  3. Detailed analysis of correlative data, exploring biomarkers, immune responses, and molecular profiles associated with mRNA CAR activity. Key Focus: Linking correlative data to clinical outcomes and optimizing therapeutic potential.

  4. Introduction to innovative receptor designs and their role in expanding the applicability of mRNA CAR therapies. Key Focus: Engineering receptors to improve specificity, durability, and therapeutic versatility.

Speakers:

Daniel Getts, Founder & Chief Financial Officer – Myeloid Therapeutics

Matthew Maurer – Chief Medical Officer – Myeloid Therapeutics

Robert Hofmeister – Chief Scientific Officer – Myeloid Therapeutics

Phil Darcy - NHMRC L3 Investigator Fellow and Laboratory Head Cancer Immunotherapy - Peter MacCallum Cancer Centre

Alex Swarbreck - Principal Research Fellow & Co-Lead of the Cancer Ecosystems Program - Garvan Institute of Medical Research

Friday 14th February

1:15pm - 2:15pm (Lunchtime)

Lunch will be served

Proudly brought to you by:

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.

Workshop Title: “CRISPR Screens, TCR/BCR Sequencing and other approaches for Cancer Drug Target and Biomarker Discovery and Validation”

Overview coming soon…

Saturday 15th February

1:15pm - 2:15pm (Lunchtime)

Lunch will be served

Proudly brought to you by: